Nothing Special   »   [go: up one dir, main page]

DE69307702D1 - Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit - Google Patents

Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit

Info

Publication number
DE69307702D1
DE69307702D1 DE69307702T DE69307702T DE69307702D1 DE 69307702 D1 DE69307702 D1 DE 69307702D1 DE 69307702 T DE69307702 T DE 69307702T DE 69307702 T DE69307702 T DE 69307702T DE 69307702 D1 DE69307702 D1 DE 69307702D1
Authority
DE
Germany
Prior art keywords
fluoroallylamine
fluorophenethyl
disease
treating alzheimer
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69307702T
Other languages
English (en)
Other versions
DE69307702T2 (de
Inventor
Ian Mcdonald
Michael Palfreyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69307702D1 publication Critical patent/DE69307702D1/de
Publication of DE69307702T2 publication Critical patent/DE69307702T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69307702T 1992-05-27 1993-04-14 Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit Expired - Fee Related DE69307702T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88867192A 1992-05-27 1992-05-27
PCT/US1993/003522 WO1993024120A1 (en) 1992-05-27 1993-04-14 USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE

Publications (2)

Publication Number Publication Date
DE69307702D1 true DE69307702D1 (de) 1997-03-06
DE69307702T2 DE69307702T2 (de) 1997-05-28

Family

ID=25393634

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69307702T Expired - Fee Related DE69307702T2 (de) 1992-05-27 1993-04-14 Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit

Country Status (15)

Country Link
EP (1) EP0642338B1 (de)
JP (1) JPH07507299A (de)
KR (1) KR950701518A (de)
AT (1) ATE147978T1 (de)
AU (1) AU672401B2 (de)
CA (1) CA2135752C (de)
DE (1) DE69307702T2 (de)
DK (1) DK0642338T3 (de)
ES (1) ES2101311T3 (de)
GR (1) GR3022608T3 (de)
HU (1) HUT72316A (de)
MX (1) MX9303074A (de)
NO (1) NO944524D0 (de)
WO (1) WO1993024120A1 (de)
ZA (1) ZA933567B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684545B2 (en) * 1993-09-24 1997-12-18 Merrell Pharmaceuticals Inc. Transdermal device containing (E)-2-(P-fluorophenethyl)-3-fluoroallylamine for the treatment of Alzheimer's disease
US5488188A (en) * 1994-09-29 1996-01-30 Merrell Dow Pharmaceuticals Inc. Process for the preparation of (E)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane, novel processes for preparing an intermediate thereof, and novel intermediates thereof
US5599986A (en) * 1994-09-29 1997-02-04 Hoechst Marion Roussel Inc. Process for the preparation of alkali metal salts of diformylamide
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
EP1870097A1 (de) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamidederivate zur Behandlung von kognitiven Störungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335897C (en) * 1987-06-16 1995-06-13 Ian A. Mcdonald (e)-2-(p-fluorophenethyl)-3-fluoroallylamine

Also Published As

Publication number Publication date
ATE147978T1 (de) 1997-02-15
AU3978293A (en) 1993-12-30
EP0642338B1 (de) 1997-01-22
MX9303074A (es) 1994-01-31
HUT72316A (en) 1996-04-29
WO1993024120A1 (en) 1993-12-09
DE69307702T2 (de) 1997-05-28
AU672401B2 (en) 1996-10-03
ZA933567B (en) 1993-12-13
NO944524L (no) 1994-11-25
CA2135752A1 (en) 1993-12-09
CA2135752C (en) 1998-07-14
JPH07507299A (ja) 1995-08-10
HU9403384D0 (en) 1995-02-28
KR950701518A (ko) 1995-04-28
DK0642338T3 (da) 1997-02-10
NO944524D0 (no) 1994-11-25
EP0642338A1 (de) 1995-03-15
GR3022608T3 (en) 1997-05-31
ES2101311T3 (es) 1997-07-01

Similar Documents

Publication Publication Date Title
DE69322957D1 (de) L - Deprenyl zur Behandlung von makulärer Degeneration
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69516110D1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
MY104521A (en) Treatment of depression.
DE69313261D1 (de) Verwendung von LACTOFERRIN zur Herstellung eines THERAPEUTISCHEN MITTELS zur Behandlung von RHEUMATISMUS
RU94011321A (ru) Способ профилактики и лечения заболеваний кожи
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
RU93046326A (ru) Способ лечения медикаментозных эзофаго-гингиво-стоматитов

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee